PT  - JOURNAL ARTICLE
AU  - Simon Tiberi
AU  - Marie-Christine Payen
AU  - Giovanni Sotgiu
AU  - Lia D'Ambrosio
AU  - Valentina Alarcon Guizado
AU  - Jan Willem Alffenaar
AU  - Marcos Abdo Arbex
AU  - Jose A. Caminero
AU  - Rosella Centis
AU  - Saverio De Lorenzo
AU  - Mina Gaga
AU  - Gina Gualano
AU  - Aurora Jazmín Roby Arias
AU  - Anna Scardigli
AU  - Alena Skrahina
AU  - Ivan Solovic
AU  - Giorgia Sulis
AU  - Marina Tadolini
AU  - Onno W. Akkerman
AU  - Edith Alarcon Arrascue
AU  - Alena Aleska
AU  - Vera Avchinko
AU  - Eduardo Henrique Bonini
AU  - Félix Antonio Chong Marín
AU  - Lorena Collahuazo López
AU  - Gerard de Vries
AU  - Simone Dore
AU  - Heinke Kunst
AU  - Alberto Matteelli
AU  - Charalampos Moschos
AU  - Fabrizio Palmieri
AU  - Apostolos Papavasileiou
AU  - Antonio Spanevello
AU  - Dante Vargas Vasquez
AU  - Pietro Viggiani
AU  - Veronica White
AU  - Alimuddin Zumla
AU  - Giovanni Battista Migliori
TI  - Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of MDR- and XDR-TB
AID  - 10.1183/13993003.02146-2015
DP  - 2016 Apr 01
TA  - European Respiratory Journal
PG  - 1235--1243
VI  - 47
IP  - 4
4099  - http://erj.ersjournals.com/content/47/4/1235.short
4100  - http://erj.ersjournals.com/content/47/4/1235.full
SO  - Eur Respir J2016 Apr 01; 47
AB  - No large study has ever evaluated the efficacy, safety and tolerability of meropenem/clavulanate to treat multidrug- and extensively drug-resistant tuberculosis (MDR- and XDR-TB). The aim of this observational study was to evaluate the therapeutic contribution, effectiveness, safety and tolerability profile of meropenem/clavulanate added to a background regimen when treating MDR- and XDR-TB cases.Patients treated with a meropenem/clavulanate-containing regimen (n=96) showed a greater drug resistance profile than those exposed to a meropenem/clavulanate-sparing regimen (n=168): in the former group XDR-TB was more frequent (49% versus 6.0%, p<0.0001) and the median (interquartile range (IQR)) number of antibiotic resistances was higher (8 (6–9) versus 5 (4–6)). Patients were treated with a meropenem/clavulanate-containing regimen for a median (IQR) of 85 (49–156) days.No statistically significant differences were observed in the overall MDR-TB cohort and in the subgroups with and without the XDR-TB patients; in particular, sputum smear and culture conversion rates were similar in XDR-TB patients exposed to meropenem/clavulanate-containing regimens (88.0% versus 100.0%, p=1.00 and 88.0% versus 100.0%, p=1.00, respectively). Only six cases reported adverse events attributable to meropenem/clavulanate (four of them then restarting treatment).The nondifferent outcomes and bacteriological conversion rate observed in cases who were more severe than controls might imply that meropenem/clavulanate could be active in treating MDR- and XDR-TB cases.Meropenem/clavulanate is effective and safe to treat MDR- and XDR-TB in comparison with controls http://ow.ly/XG75j